Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...

BLA for subcutaneous formulation of Leqembi® accepted in China

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
Seeking Alpha

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that ...
Nasdaq

Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results

– IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung ...
Cure Today

FDA Approves Subcutaneous Tecentriq Formulation

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...
Seeking Alpha

New Subcutaneous Formulation of OPDIVO® Receives Positive INESSS Recommendation for Multiple Tumour Types

MONTREAL, Sept. 23, 2025 /CNW/ - Bristol Myers Squibb Canada (BMS) today announced that the Institut national d'excellence en santé et en services sociaux (INESSS) has issued a positive recommendation ...
Targeted Oncology

FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Cure Today

Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
MarketWatch

$233 Bn Subcutaneous Biologics Market Industry Trends and Global Forecasts, 2025-2035 - ResearchAndMarkets.com

The "Subcutaneous Biologics Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biologic, Type of Therapy, End User, Payment Method Employed, Therapeutic Area, Drug Delivery ...
Morningstar

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

This formulation of small molecule ASC30 SQ injection is advancing into further clinical trials to evaluate clinical efficacy at doses above 100 mg. The other two formulations, which have different ...

BioArctic: BLA for subcutaneous formulation of Leqembi accepted in China

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
Nasdaq

Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results

IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung ...